Abstract:Introduction/Background Cervical cancer is a prevalent gynecological malignancy in China, with limited treatment options for advanced stages. Despite platinum-based chemotherapy, patients with advanced cervical cancer face a median survival of only 16.8 months, emphasizing the need for alternative therapies. PIK3CA mutations are frequently observed in cervical cancer, leading to the constitutive activation of the PI3K-AKT pathway. Although PI3K inhibitors, like alpelisib (BYL719), show promise, challenges persist, including efficacy prediction and limited single-drug effectiveness. Methodology Utilizing CRISPR/Cas9 technology, we employed a negative selection strategy to identify efficacy biomarkers for PI3Kα inhibitors in cervical cancer. We knocked down KMT2D and established stable cell lines, assessing responses to BYL719 through CCK8 assays, IC50 calculations, apoptosis, and cell cycle analyses. To elucidate the mechanism, CUT&Tag combined with RNA-seq analysis was performed, exploring the impact of KMT2D on ITGB6 expression and downstream FAK Y397 phosphorylation. In vivo verification involved subcutaneous tumorigenic administration experiments in nude mice with KMT2D knockdown cell lines. Results KMT2D silencing increased BYL719 sensitivity, apoptosis, and cell cycle arrest in vitro. Overexpression of KMT2D conferred resistance. Mechanistically, KMT2D regulated ITGB6 expression, impacting FAK Y397 phosphorylation and the PI3K/AKT pathway. In vivo, KMT2D knockdown enhanced BYL719 efficacy. To address resistance, we induced PI3Kα inhibitor-resistant cell lines, revealing upregulated phosphorylation-modification-related proteins enriched in the Focal adhesion pathway. Combining BYL719 with the FAK inhibitor Defactinib reversed resistance. Conclusion Genome-wide CRISPR/Cas9 screening identified KMT2D as an efficacy biomarker for BYL719 in cervical cancer. Silencing KMT2D enhanced BYL719 sensitivity by regulating ITGB6 and FAK Y397 phosphorylation. Additionally, the combination of BYL719 and Defactinib reversed PI3Kα inhibitor resistance. This study provides insights for clinical trials, emphasizing the potential of KMT2D as a predictive marker for PI3Kα inhibitors in cervical cancer treatment. Disclosures There are no financial conflicts of interest to disclose.

The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer

Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors

Cyclin-dependent Kinase 9 Promotes Cervical Cancer Development Via AKT2/p53 Pathway.

Targeting CDK9 for Anti-Cancer Therapeutics

Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism

Effects of Cyclin-Dependent Kinase 8 Specific Sirna on the Proliferation and Apoptosis of Colon Cancer Cells

Enhancement of Cisplatin-Induced Cytotoxicity Against Cervical Cancer Spheroid Cells by Targeting Long Non-Coding RNAs.

Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells

Targeting caspase-8: a new strategy for combating hepatocellular carcinoma

Modulation of CASC2/miR-21/PTEN Pathway Sensitizes Cervical Cancer to Cisplatin.

Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer

542 the Role and Mechanism of KMT2D to Modulate PI3Kα Inhibitor Response in Cervical Cancer Identified by CRISPR/Cas9 Genome-Wide Screening

Antagonizing CDK8 Sensitizes Colorectal Cancer to Radiation Through Potentiating the Transcription of E2f1 Target Gene Apaf1

Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy

Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance

Targeting RNF8 Effectively Reverses Cisplatin and Doxorubicin Resistance in Endometrial Cancer.

Caspase-8: A key protein of cross-talk signal way in "PANoptosis" in cancer

The RNA-binding protein LRPPRC promotes resistance to CDK4/6 inhibition in lung cancer

[Expression of Caspase-8 in Non-Small Cell Lung Cancer and Its Role in Invasion and Metastasis of Lung Cancer A549 Cells].

Highlighting the Major Role of Cyclin C in Cyclin-Dependent Kinase 8 Activity through Molecular Dynamics Simulations

CRISPR/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer